مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Normal view MARC view ISBD view

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER [electronic resource]

By:
  • Bihani, Teeru
Contributor(s):
  • Patel, Hitisha K
  • Arlt, Heike
  • Tao, Nianjun
  • Jiang, Hai
  • Brown, Jeffrey L
  • Purandare, Dinesh M
  • Hattersley, Gary
  • Garner, Fiona
Producer: 20180430Description: 4793-4804 p. digitalISSN:
  • 1557-3265
Subject(s):
  • Animals
  • Antineoplastic Agents -- pharmacology
  • Antineoplastic Combined Chemotherapy Protocols -- pharmacology
  • Breast Neoplasms -- drug therapy
  • Cell Line, Tumor
  • Everolimus -- administration & dosage
  • Female
  • Humans
  • MCF-7 Cells
  • Mice, Inbred BALB C
  • Mice, Nude
  • Piperazines -- administration & dosage
  • Pyridines -- administration & dosage
  • Receptors, Estrogen -- genetics
  • Selective Estrogen Receptor Modulators -- administration & dosage
  • Tetrahydronaphthalenes -- administration & dosage
  • Tumor Burden -- drug effects
  • Xenograft Model Antitumor Assays
Online resources:
  • Available from publisher's website
In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 23
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Log in to your account to post a comment.

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER

APA

Bihani T., Patel H. K., Arlt H., Tao N., Jiang H., Brown J. L., Purandare D. M., Hattersley G. & Garner F. (20180430). Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Bihani Teeru, Patel Hitisha K, Arlt Heike, Tao Nianjun, Jiang Hai, Brown Jeffrey L, Purandare Dinesh M, Hattersley Gary and Garner Fiona. 20180430. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Bihani T., Patel H. K., Arlt H., Tao N., Jiang H., Brown J. L., Purandare D. M., Hattersley G. and Garner F. (20180430). Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Bihani Teeru, Patel Hitisha K, Arlt Heike, Tao Nianjun, Jiang Hai, Brown Jeffrey L, Purandare Dinesh M, Hattersley Gary and Garner Fiona. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20180430.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site